Most, if not all, currently available drugs for Parkinson disease
address dopaminergic loss and relieve symptoms. However,
their adverse effects can be limiting and they do not address
disease progression. Moreover, nonmotor features of Parkinson
disease such as depression, dementia, and psychosis are
now recognized as important and disabling. A cure remains
elusive. However, promising interventions and agents are
emerging. As an example, people who exercise regularly are
less likely to develop Parkinson disease, and if they develop it,
they tend to have slower progression.